Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
← catalyst calendarNCT07325461 · readout in 194 d
Sponsored by Tandem Diabetes Care, Inc. (industry) · TNDM — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-18 | actual | When the study began enrolling |
| Primary completion | 2027-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Intervention
- Device: SteadiSet Infusion Set
Primary outcome
what the primary-completion date above is the date OF7 Day Survival of Infusion Set for Primary Outcome Measure
measured 6 weeks
Permalink · TNDM's whole pipeline · Catalyst calendar · Every registered study · What changed